Ranexa 500 (ranolazine) tablets with prolonged release 500 mg. №60

Description

Ranexa 500 (ranolazine) tablets with prolonged release 500 mg. №60

Composition

active substance: ranolazine;

1 film-coated tablet contains ranolazine 500 mg;

auxiliary substances: microcrystalline cellulose, copolymer of methacrylic acid and ethyl acrylate (1:1), hypromellose, magnesium stearate, sodium hydroxide, polyethylene glycol 3350, partially hydrolyzed polyvinyl alcohol, talc, titanium dioxide (E 171), iron oxide yellow (E 172), red iron oxide (E 172), carnauba wax;

1 film-coated tablet contains ranolazine 1000 mg;

auxiliary substances: microcrystalline cellulose, copolymer of methacrylic acid and ethyl acrylate (1:1), hypromellose, magnesium stearate, sodium hydroxide, glycerin triacetate, lactose monohydrate, polyethylene glycol 3350, titanium dioxide (E 171), iron oxide yellow (E 172), wax carnauba

Medicinal form

Long-acting tablets.

The main physical and chemical properties:

• 500 mg tablets: light orange, film-coated, convex on both sides, oval-shaped tablets, embossed with “500” on one side, the other side is smooth;
• 1000 mg tablets: pale yellow, film-coated, convex on both sides, oval-shaped tablets, embossed with “1000” on one side, the other side is smooth.

Pharmacotherapeutic group

Other cardiological means. Ranolazine.
ATX code C01E B18.

Pharmacological properties

The drug Ranexa 500 is a cardiac drug, the action of which is due to the suppression of the late flow of sodium ions into myocardial cells, a decrease in intracellular sodium accumulation and a decrease in the excess of intracellular calcium ions, which helps to relax the myocardium and reduce gastro-diastolic tension.

Indications for use

The drug is used and prescribed for stable angina pectoris.

Contraindications

Ranexa 500 is usually very well tolerated, but still there are contraindications to the use of the drug, such as: renal and hepatic failure, individual intolerance to the constituent substances, children under 18 years of age. Concomitant use with potent CYP3A4 inhibitors (itraconazole, voriconazole, ketoconazole, posaconazole, telithromycin, clarithromycin, HIV protease inhibitors, nefazodone, etc.), as well as in combination with antiarrhythmic drugs of class Ia (quinialidine) or class III ( dofetilide and others), except for amiodar.

Pregnancy and breastfeeding period

The use of Ranexa 500 is contraindicated during pregnancy and lactation.

Mode of application

Ranexa 500 is taken regardless of food, without chewing, without breaking.
The recommended dose is 500 mg 2 times a day. After 2-4 weeks of use, if necessary, the dose can be increased to 1000 mg 2 times a day. The maximum dose per day should not exceed 2000 mg.

If taking the pills caused side effects, for example, nausea, dizziness, vomiting, the dose is reduced by 500 mg, but if the reaction to the drug persists, it is necessary to stop treatment.

Overdose

An overdose of Ranex 500 often leads to dizziness, vomiting and nausea.
In case of poisoning with pills, symptomatic treatment should be applied.

Adverse reactions

Side effects when using Ranexa 500 are manifested in the form of: anorexia, dehydration, decreased appetite, anxiety, confusion, insomnia, dizziness, lethargy, headache, hypesthesia, loss of consciousness, drowsiness and tremor.

Also possible: blurred vision, hallucinations, visual disturbances, diplopia hypotension, hot flashes, cold extremities, cough, shortness of breath, nosebleeds, tinnitus, a feeling of a lump in the throat, nausea, constipation, abdominal pain, vomiting, dry mouth.

Taking pills can cause: dyspepsia, stomach discomfort, flatulence, pancreatitis, oral hypesthesia, erosive duodenitis, pruritus, angioedema, hyperhidrosis, allergic dermatitis, cold sweat, urticaria, rash, muscle cramps, pain in the extremities, edema , dysuria, chromaturia, acute renal, urinary retention, failure, erectile dysfunction, asthenia, fatigue and peripheral edema.